Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

JDR Dermatology Research LLC

Neither a doctor nor a teaching hospital

Research payments

$284,515

112 payments

Through program year 2025, JDR Dermatology Research LLC is reported as receiving $284,515 in research payments, across 112 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $101,263 5
2024 Research $4,446 46
2023 Research $79,433 27
2022 Research $8,292 6
2021 Research $647 1
2020 Research $65,993 17
2019 Research $24,442 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $93,863 4 payments
  2. Journey Medical Corporation $78,097 7 payments
  3. VYNE Pharmaceuticals Inc. $29,211 5 payments
  4. Dr.Reddy's Laboratories,Inc. $17,692 9 payments
  5. Galderma Research & Development, LLC $12,973 3 payments
  6. Dermavant Sciences, Inc. $12,780 70 payments
  7. Pfizer Inc. $12,100 3 payments
  8. Regeneron Pharmaceuticals, Inc. $12,079 8 payments
  9. Amgen Inc. $7,847 1 payment
  10. Sanofi US Services Inc. $7,400 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $93,863 4 payments
  2. Dfd-29-Cd-005 $67,500 4 payments
  3. Fx2016-40 $29,211 5 payments
  4. Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis $17,692 9 payments
  5. A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Compare Efficacy and Safety of Trifarotene (Cd5789) Cream When Used With An Oral Antibiotic for the Treatment of Severe Acne Vulgaris $12,973 3 payments
  6. Dfd-29-Cd-004 $10,597 3 payments
  7. Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) $7,847 1 payment
  8. A Phase 3 Randomized Doubleblind Placebocontrolled Multicenter Study Investigating the Efficacy and Safety Ofpf04965842 Coadministered With Background Medicated Topical Therapy in Adolescent Participants 12 to 18 Years of Age With Moderatetosevere Atopic Dermatitis $7,600 2 payments
  9. A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis $7,550 1 payment
  10. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults $7,400 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $4,000 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record